TP53 and FGFR3 gene mutation assessment in urine: Pilot study for bladder cancer diagnosis

Anticancer Research

Volumn 35, Issue 9, 2015, Pages 4915-4922

  Noel, Nicolas ^a   Couteau, Jerome ^b   Maillet, Geraldine ^b   Gobet, Françoise ^a   D'aloisio, Françoise ^d   Minier, Christophe ^c   Pfister, Christian ^a,d  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b TOXEM Laboratory   (France)

^c Unité d écotoxicologie in vitro et in vivo   (France)

^d INSERM   (France)

Author keywords

Bladder cancer; FGFR3; Mutation phenotype; TP53; Urine sediment

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FUNCTIONAL ANALYSIS OF SEPARATED ALLELE IN YEAST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSTICS; MUTATIONAL ANALYSIS; PILOT STUDY; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY; URINE SEDIMENT; AGAR GEL ELECTROPHORESIS; BLADDER TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; MUTATION; PATHOLOGY; PHENOTYPE; URINE;

DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, AGAR GEL; HUMANS; MUTATION; NEOPLASM STAGING; PHENOTYPE; PILOT PROJECTS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84939646869     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293, 2009.
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, Van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J and Rouprêt: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4): 639-653, 2013.
4. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L,Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK and de Medina SG: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63(23): 8108-8112, 2003.
5. Van Rhijn BW, Van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER and Zwarthoff EC: FGFR3 and TP53 characterize alternative genetic pathways in pathogenesis of urothelial cell carcinoma. Cancer Res 64(6): 1911-1914, 2004.
6. Lamy A, Gobet F, Laurent M, Blanchard F, Varin C, Moulin C, Andreou A, Frebourg T and Pfister C: Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 176: 2686-2689, 2006.
7. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP and Radvanyi F: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158: 1955-1959, 2001.
8. Sibley K,Cuthbert D and Knowles M: Loss of heterozygosity at 4p16.3 and mutations of FGFR3 in transitional cell carcinoma. Oncogene 20: 686-691, 2001.
9. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM and Omtoft TF: Role of activating FGFR3 mutations in the development of bladder tumors. Clin Cancer Res 11: 7709-7719, 2005.
10. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492): 315-322, 2014.
11. Smal MP, Rolevich AI, Polyakov SL, Krasny SA and Goncharova RI: FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients. Exp Oncol 36(4): 246-251, 2014.
12. Pfister C, Roupret M, Neuzillet Y, Larre S, Pignot G, Quintens H, Houede N, Comperat E, Colin P, Roy C, Davin JL, Guy L, Irani J, Lebret T, Coloby P and Soulie M: CCAFU Recommendations 2013:Bladder carcinoma. Prog Urol 23(Suppl 2): 105-125, 2013.
13. Chomczynski P and Sacchi N: The single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nature Protocols 1(2): 581-585, 2006.
14. Menke T and Warnecke J: Improved conditions for isolation and quantification of RNA in urine specimens. Ann NY Acad Sci 1022: 185-189, 2004.
15. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L and Benhattar J: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 25(92): 3963-3967, 1995.
16. Pfister C, Flaman JM, Martin C, Grise P and Frebourg T: Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors. J Urol 161(6): 1973-1975, 1999.
17. Robert V, Michel P, Flaman JM, Chiron A, Martin C, Charbonnier F, Paillot B and Frebourg T: High frequency in oesophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis 21(4): 563-565, 2000.
18. Van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN and Zwarthoff EC: A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11(21): 7743-7748, 2005.
19. Eble J: World Health Organization classification of tumors. Pathology and genetics of tumors oft he urinary system and male genital organs. Lyon: IARC Press, 2004.
20. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP,Schmütte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG and Jones PA: Two molecular pathways to transitional cell carcinoma of the bladder.Cancer Res 54(3): 784-788, 1994.
21. Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, de The H, Sibony M, Denoux Y, Molinie V, Herault A, Lepage ML, Maille P, Renou A, Vordos D, Abbou CC, Bakkar A, Asselain B, Kourda N, El Gaaied A, Leroy K, Laplanche A, Benhamou S, Lebret T, Allory Y and Radvanyi F: A metaanalysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.PLos One 7(12): e 48993, 2012.
22. Watanabe J, Nishiyama H,Okubo K, Takahashi T, Toda Y, Habuchi T, Kakehi Y, Tada M and Ogawa O: Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.Urology 63(5): 989-993 2004.
23. Eissa S, Zohny SF, Zekri AR, El-Zayat TM and Maher AM: Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol 27(4): 1286-1294, 2010.
24. Prescott JL, Montie J, Pugh TW, McHugh T and Veltri RW: Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens.Cancer 91(11): 2127-2135, 2001.
25. Schlichtholz B, Presler M and Matuszewski M: Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.Carcinogenesis 12: 2319-2323, 2004.